GI Flashcards
Drug class for Loperamide
anti-diarrheal
MoA for Loperamide
inhibition of presynaptic cholinergic nerves in colonic submucosal & myenteric plexus slows transit time
Indications for Loperamide
mild-moderate diarrhea w/out obstructions, IBD, IBS
Drug class for Kaolin-Pectin
anti-diarrheal
MoA for Kaolin-Pectin
a clay (Kaolin) & a plant polysaccharide (Pectin) combination that absorbs fluids & bacterial toxins
Indications for Kaolin-Pectin
mild diarrhea
Drug class for Fiber
anti-diarrheal
MoA for Fiber
absorbs & binds fluids; provides stool bulk
Indications for Fiber
mild-moderate diarrhea, constipation
Drug class for Bismuth Subsalicylate
anti-diarrheal
MoA for Bismuth Subsalicylate
anti-secretory (salicylate) & anti-microbial (bismuth) action
Indications for Bismuth Subsalicylate
symptomatic tx of mild, nonspecific diarrhea, traveler’s diarrhea, as part of multi-drug regimen for H pylori
Drug class for Octreotide
anti-diarrheal
MoA for Octreotide
synthetic analogue of somatostatin w/ longer half-life; inhibits bowel secretion; dose-related impact on mobility; splanchnic arteriole constriction
Indications for Octreotide
diarrhea secondary to dysmotility, carcinoid, VIP-oma, pancreatic fistulas, vagotomy, dumping syndrome, short bowel syndrome, HIV diarrhea, GI bleeding
Drug class for Senokot
anti-diarrheal
MoA for Senokot
stimulates enterocytes, enteric neurons, GI smooth muscle inducing low-grade inflammation, fluid accumulation & stimulate intestinal motility
Indications for Senokot
constipation (without bowel obstruction)
Drug class for 5ASA
5ASA anti-inflammatory
MoA for 5ASA
local colon anti-inflammatory action & systemic prostaglandin inhibition
Indications for 5ASA
ulcerative colitis, proctosigmoiditis, proctitis
Drug class for Sulfasalazine
5ASA anti-inflammatory
MoA for Sulfasalazine
local colon anti-inflammatory action & systemic prostaglandin inhibition
Indications for Sulfasalazine
ulcerative colitis, RA, Crohn’s, psoriasis
Drug class for Azathioprine
purine analogues
MoA for Azathioprine
inhibits synthesis of DNA, RNA proteins
Indications for Azathioprine
steroid sparing for steroid dependent Crohn’s disease, ulcerative colitis, maintain remission in CD; fistulizing CD; kidney transplant, RA
Drug class for Methotrexate
pruine analogues
MoA for Methotrexate
decreases protein synthesis via inhibition of dihydrofolate reductase; inhibits interleukin-1; increase release of anti-inflammatory adenosine
Indications for Methotrexate
Crohn’s, ulcerative colitis, psoriasis, RA
Drug class for Infliximab
anti-TNF alfa compounds
Indications for Infliximab
acute & maintenance tx of moderate to severe Crohn’s & ulcerative colitis
Drug class for Ursodiol
gallstone dissolution agent
MoA for Ursodiol
reduces hepatic secretion of cholesterol
Indications for Ursodiol
gallstones, prevention of stones in rapid weight loss; primary biliary cirrhosis
Drug class for Lubiprostone
laxative calcium channel activation
MoA for Lubiprostone
activates calcium channels to increase bowel fluid secretion & motility
Indications of Lubiprostone
chronic constipation, IBS, opioid-induced constipation
Drug class for Linaclotide
laxative cGMP agonist
MoA for Linaclotide
agonizes guanylate cyclase-C on luminal surface of bowel epithelium, increases cGMP resulting in chloride & bicarbonate secretion into intestinal lumen
Indications for Linaclotide
IBS-C or chronic idiopathic constipation in adults
Drug class for MiraLax
osmotic laxative
MoA for MiraLax
causes water retention in stool & increases stool frequency
Indications for MiraLax
occasional constipation; short term use
Drug class for Lactulose
osmotic laxative
MoA for Lactulose
osmotic agent
Indications for Lactulose
px/tx portal systemic encephalopathy (PSE)
Drug class for MgCitrate
magnesium laxative
MoA for MgCitrate
osmotic retention of bowel fluid distending colon & increasing perstalsis
Indications for MgCitrate
occasional constipation; study prep
Drug class for Natalizumab
anti-integrin
MoA for Natalizumab
inhibits integrin on leukocyte surface & inhibit their adhesion to vascular endothelium & their migration into tissue
Indications for Natalizumab
subset of patients w/ moderate to severe Crohn’s who have failed other tx
Drug class for Ranitidine
H2R antagonist
MoA for Ranitidine
competitively inhibits H2 receptors of gastric parietal cells reduce basal & stimulated acid production
Indications for Ranitidine
PUD, GERD
Drug class for Omeprazole & Pantoprazole
PPI
MoA for Omeprazole & Pantoprazole
inhibits basal & stimulate parietal cell proton pump acid secretion
Indications for Omeprazole & Pantoprazole
PUD, GERD, prevention of NSAID ulcers; stress ulcer px in critically ill
Drug class for Sucralfate
mucosal surfactant